

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that it has signed a corporate transaction by means of which GIC, the sovereign wealth fund of Singapore, have entered into a definitive agreement under which GIC will invest approx. US\$1 Bn in Grifols' wholly-owned US subsidiary Biomat USA, Inc. ("Biomat"). In exchange, GIC will acquire a minority stake in Biomat, in the form of newly issued preferred non-voting stock.

Biomat (together with its subsidiaries) holds a plasma collection business with 296 plasma collection centers throughout the territory of the United States.

Grifols will continue to control all aspects of the day-to-day management of Biomat and, through a long-term plasma supply agreement, all plasma collected by Biomat and its subsidiaries will continue to be supplied to Grifols for the further manufacturing of plasma derived products.

Grifols will apply all proceeds from GIC's investment to repay debt

The consummation of GIC's strategic investment in Grifols is subject to certain closing conditions, including the obtainment of applicable regulatory authorizations, such as the Committee on Foreign Investments in the United States (CFIUS).

In Barcelona, on 30 June 2021

Nuria Martín Barnés
Secretary to the Board of Directors